CAPRICOR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.3 USD | -2.21% |
|
-3.11% | +8.38% |
Presentation Operator MessageOperator (Operator)Greetings and welcome to the Capricor Therapeu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.
Calendar
04:05pm
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.3
USD
Average target price
21
USD
Spread / Average Target
+296.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.38% | 167M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +0.09% | 22.25B | |
| -13.14% | 22.09B | |
| -7.87% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- CAPR Stock
- News Capricor Therapeutics, Inc.
- Transcript : Capricor Therapeutics, Inc., Q3 2020 Earnings Call, Nov 12, 2020